Senior writer Tina Hesman Saey is a geneticist-turned-science writer who covers all things microscopic and a few too big to be viewed under a microscope. She is an honors graduate of the University of Nebraska-Lincoln where she did research on tobacco plants and ethanol-producing bacteria. She spent a year as a Fulbright scholar at the Georg-August University in Göttingen, Germany, studying microbiology and traveling. Her work on how yeast turn on and off one gene earned her a Ph.D. in molecular genetics at Washington University in St. Louis. Tina then rounded out her degree collection with a master’s in science journalism from Boston University. She interned at the Dallas Morning News and Science News before returning to St. Louis to cover biotechnology, genetics and medical science for the St. Louis Post-Dispatch. After a seven year stint as a newspaper reporter, she returned to Science News. Her work has been honored by the National Academies of Sciences, Engineering and Medicine, the Endocrine Society, the Genetics Society of America and by journalism organizations.
Trustworthy journalism comes at a price.
Scientists and journalists share a core belief in questioning, observing and verifying to reach the truth. Science News reports on crucial research and discovery across science disciplines. We need your financial support to make it happen – every contribution makes a difference.
All Stories by Tina Hesman Saey
-
Health & Medicine
Oxford and AstraZeneca say their COVID-19 vaccine works too
A third major vaccine, which may be easier to distribute than others, appears to prevent disease and maybe transmission of the coronavirus.
-
Health & Medicine
Here’s why COVID-19 vaccines like Pfizer’s need to be kept so cold
Both Pfizer and Moderna built their vaccines on RNA. Freezing them keeps their fragile components from breaking down.
-
Health & Medicine
New Pfizer results show its COVID-19 vaccine is nearly 95% effective
With final results – including showing its vaccine is 94 percent effective in the elderly – Pfizer is poised to request emergency use authorization.
-
Health & Medicine
Coronavirus cases are skyrocketing. Here’s what it will take to gain control
Basic public health measures can still curb COVID-19, if everyone does their part.
-
Health & Medicine
How two immune system chemicals may trigger COVID-19’s deadly cytokine storms
A study in mice hints at drugs that could be helpful in treating severe coronavirus infections.
-
Health & Medicine
Remdesivir doesn’t reduce COVID-19 deaths, a large WHO trial finds
An international study of more than 11,000 people finds that remdesivir doesn’t prevent deaths from COVID-19, but the drug may still be useful.
-
Genetics
Gene-editing tool CRISPR wins the chemistry Nobel
A gene-editing tool developed just eight years ago that has “revolutionized the life sciences” nabbed the 2020 Nobel Prize in chemistry.
-
Health & Medicine
Hepatitis C discoveries win 2020 Nobel Prize in physiology or medicine
The 2020 medicine Nobel recognizes work that found that a novel virus was to blame for chronic hepatitis and led to a test to screen blood donations.
-
Health & Medicine
Neandertal genes in people today may raise risk of severe COVID-19
People in South Asia and Europe are more likely to carry a genetic heirloom from Neandertals linked to susceptibility to the coronavirus.
-
Health & Medicine
What will happen when COVID-19 and the flu collide this fall?
As the Northern Hemisphere braces for a coronavirus-flu double hit, it’s unclear if it’ll be a deadly combo or one virus will squeeze out the other.
-
Health & Medicine
Here’s what pausing the AstraZeneca-Oxford coronavirus vaccine trial really means
A coronavirus vaccine trial was paused after a volunteer had a possible adverse reaction. Such routine measures help ensure new vaccines are safe.
-
Genetics
Strict new guidelines lay out a path to heritable human gene editing
But scientists say making changes in DNA that can be passed on to future generations still isn’t safe and effective, yet.